The medication, also approved in the United States, is the first approved monoclonal antibody that specifically blocks the ...

With the help of prescription medications and a whole lot of moisturizing, it’s possible to keep dermatitis under control.

Nemluvio has received approval from the European Commission to treat moderate to severe atopic dermatitis and prurigo ...

Galderma (SWX:GALD) today announced that the European Commission has approved Nemluvio for both moderate-to-severe atopic ...

The FDA has granted a fast track designation to rezpegaldesleukin for treating patients aged 12 years and older with moderate ...

Throw dermatitis into the mix, and the frustration compounds. No one wants to go about the day dealing with an uncomfortable, itchy rash. Dermatitis refers to a number of skin conditions driven by ...

Nemluvio is now the first approved monoclonal antibody that specifically targets interleukin-31 receptor alpha ...

The clinical and financial implications of inpatient dermatology were examined, highlighting the need for systemic changes to ...

Nemluvio, which was also approved for prurigo nodularis, becomes Galderma’s first approved biologic in its dermatology ...

Many skin conditions appear differently in melanated skin, leading to misdiagnosis and poor treatment. Understanding these ...

Alphyn, a clinical-stage dermatology company developing first-in-class Multi-Target Therapeutics®, announced today that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New ...